Volume 82 | ESPE2014 | Next issue

ESPE 2014

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

Card image cap
Dublin, Ireland; 18-20 September 2014. Further information

Free Communications

Bone & Mineral

Asfotase Alfa: Sustained Improved Growth and Function with Extended Treatment in Children with Hypophosphatasia
aShriners Hospitals for Children, St Louis, Missouri, USA; bUniversity of Manitoba, Winnipeg, Manitoba, Canada; cAlexion Pharmaceuticals, Cheshire, Connecticut, USA; dAlexion Pharmaceuticals, Cambridge, Massachusetts, USA
hrp0082fc2.1
Hypophosphatasia: Gross Motor Function and Height Improvement in Infants and Young Children Treated with Asfotase Alfa for up to 3 Years
aSheffield Children’s Hospital, Sheffield, UK; bVanderbilt Children’s Hospital, Nashville, Tennessee, USA; cNebraska Medical Center, Omaha, Nebraska, USA; dAlexion Pharmaceuticals, Cambridge, Massachusetts, USA; eAlexion Pharmaceuticals, Cheshire, Connecticut, USA; fUniversity of North Carolina, Chapel Hill, North Carolina, USA; gShriners Hospitals for Children, St Louis, Missouri, USA
hrp0082fc2.2
Pharmacokinetics and Pharmacodynamics of a Human Monoclonal Anti-Fibroblast Growth Factor 23 Antibody (KRN23) Following 4 Month Intra-Dose Escalation in Adults with X-Linked Hypophosphatemia
aKyowa Hakko Kirin Pharma, Inc., Princeton, New Jersey, USA; bIndiana University School of Medicine, Indianapolis, Indiana, USA; cThe Methodist Hospital, Houston, Texas, USA; dDuke Clinical Bone Laboratories, Duke University Medical Center, Durham, North Carolina, USA; eShriners Hospital for Children, Montreal, Quebec, Canada; fUniversity of California, San Francisco, California, USA; gYale Center for X-Linked Hypophosphatemia, Yale University School of Medicine, New Haven, Connecticut, USA
hrp0082fc2.5
Efficacy and Safety Following 4 Monthly s.c. Doses of a Human Anti-Fibroblast Growth Factor 23 Antibody (KRN23) in Adults with X-linked Hypophosphatemia
aIndiana University School of Medicine, Indianapolis, Indiana, USA; bKyowa Hakko Kirin Pharma, Inc., Princeton, New Jersey, USA; cThe Methodist Hospital, Houston, Texas, USA; dDuke Clinical Bone Laboratories, Duke University Medical Center, Durham, North Carolina, USA; eShriners Hospital for Children, Montreal, Quebec Canada; fUniversity of California, San Francisco, California, USA; gYale Center for X-Linked Hypophosphatemia, Yale University School of Medicine, New Haven, Connecticut, USA
hrp0082fc2.6